• By Elite Wealth
  • / September 1, 2021
  • / whatsnew
IPO-Note Vijaya Diagnostic Centre Limited
Rs 522 – Rs 531 per Equity share Recommendation: Subscribe

Company Profile: –

Vijaya Diagnostic Centre limited (VDCL) is the largest integrated diagnostic chain in Southern India by operating revenue andprovides one-Stop solution for Pathology and Radiology Testing Services. Under Pathology Test Servicesranging from basic biochemistry and clinical Pathology to cytogenetics and high-end molecular diagnostic tests, and radiology tests ranging from basic echocardiograms, X-rays and ultrasounds to advanced radiology tests including computerized tomography (“CT”) scans, magnetic resonance imaging (“MRI”) scans, single photon emission computed tomography (“SPECT”) and advanced positron emission tomography CT (“PET CT”). It’s Operational Network  consist 81 diagnostic Centre and 11 reference laboratories across 13 cities and towns in the states of Telangana and Andhra Pradesh and in the National Capital Region and Kolkata as on June 30, 2021.

Open Your Demat Account to Invest in Upcoming IPO’s


Vijaya Diagnostic Centre Limited

Wants To Apply Online


                                                                   Issue Details
Objects of the issue

· To achieve the benefit of listing on stock exchange

·  To make an offer for Sale of 35,688,064 Shares .



Issue Size Total issue Size – Rs. 1895.04Cr.

Offer for Sale – Rs. 1895.04Cr.

Face value  

Rs.1.00 Per Equity Share

Issue Price Rs. 522 – Rs. 531
Bid Lot 28 shares
Listing at  


Issue Opens: 1st Sep, 2021 – 3rd Sep, 2021
QIB 50% of Net Issue Offer
Retail 35% of Net Issue Offer
NIB 15% of Net Issue Offer

Financial Performance:

Financial -Performance-vijaya


Check Vijaya Diagnostic Centre Limited IPO Allotment Status

Vijaya Diagnostic Centre Limited IPO allotment status would be available soon after the IPO closure date. Usually the allotment comes within a week from the closing date which in this IPO yet to be announced.

One can check the allotment on the given below link with PAN number or Application number or DP Client Id. All you need to do is to follow these steps:-

  1. To Vijaya Diagnostic Centre LimitedIPO Allotment Status
  2. Go to Application Status
  3. Select IPO as Vijaya Diagnostic Centre Limited
  4. Enter your PAN Number or Application Id or DP Client Id.


Vijaya Diagnostic Centre Limited IPO

Application Form


Shareholding Pattern:

Shareholding Pattern Pre- Issue Post Issue
Promoters & Promoter Group 59.78% 54.78%
Public 40.22% 45.22%

Source: RHP, EWL Research



  • Fastest and largest growing Diagnostic chain with dominant position in south India.
  • Strong and consistent financial Performance.
  • Integrated diagnostics provider that offers one-stop solution at affordable price.
  • Higher and Consistent margins.

Key Highlights:

  • Revenuefrom operationsstood at Rs. 376.75 crore in FY21 grew at a CAGR of 13.5% between FY19 and FY21.
  • Individual Consumer Business contributed around 92% of the Total Revenue.
  • Net profit Stood at Rs.84.91 crore grow at a CAGR of 35.46% from FY19 to FY21.
  • EBITDA Margin was 47.22% in FY21 vs 43.68% in FY20
  • Company has significantly reduced it’s debt in FY21 from Rs.32.84 crore to Rs.4.47 crore Which makes the Company virtually debt free.
  • CFO/PAT stands at 1.54as of 30th June FY22.

Risk Factors:

  • The company’s operations are concentrated in south India, and any loss of business in such region could have an adverse effect on their business, results of operations and financial condition.
  • VDCL CEO, Sura Suprita Reddy was named in a criminal proceeding.


VDCL is a Diagnostic company that generates its revenue from Pathology and Radiology Testing Services. It offers a comprehensive range of approximately 1,610 pathology tests and follow ‘hub and spoke’ model in which specimens to be collected across multiple locations within a catchment area or a region for delivery to  reference laboratories for diagnostic testing that provides greater economies of scale and enhances consistency of testing procedures to the company.The Indian diagnostics market was valued at approximately Rs.71000crore to Rs.73000 crore in FY 2021, and is projected to reach approximately Rs.92000crore to Rs.98000crore byFY23, driven by rise in health awareness and disposable incomes, increase in demand for better healthcare facilities and quality of care of individuals, and increase in spending on preventive and wellness. The diagnostics market in Telangana and Andhra Pradesh, in which company have significant presence in, is projected to grow to approximately Rs.120 billion to Rs.130 billion by FY23.At the higher price band of Rs 531, the offer is made at P/E multiple of 63.97 times on Post Issue equity basis which is lower among peers like Dr. Lal Path labs and Metropolis health care which are trading at a P/E of 115 Times and 79.20 Times.Thus, We recommend Subscribe to the IPO for longer term.

Disclosure in pursuance of Section 19 of SEBI (RA) Regulation 2014

Elite Wealth Limited does/does not do business with companies covered in its research reports. Investors should be aware that the Elite Wealth Limited may/may not have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only information in making their investment decision and must exercise their own judgment before making any investment decision.
For analyst certification and other important disclosures, see the Disclosure Appendix, or go to Analysts employed by Elite Wealth Limited are registered/qualified as research analysts with SEBI in India.( SEBI Registration No.: INH100002300)
Disclosure Appendix
Analyst Certification (For Reports)
Israil Khan, Elite Wealth Limited,
The analyst(s) certify that all of the views expressed in this report accurately reflect my/our personal views about the subject company or companies and its or their securities. I/We also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report. Unless otherwise stated, the individuals listed on the cover page of this report are analysts in Elite Wealth Limited.
As to each individual report referenced herein, the primary research analyst(s) named within the report individually certify, with respect to each security or issuer that the analyst covered in the report, that:
(1) all of the views expressed in the report accurately reflect his or her personal views about any and all of the subject securities or issuers; and
(2) no part of any of the research analyst’s compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in the report.
For individual analyst certifications, please refer to the disclosure section at the end of the attached individual notes.
Research Excerpts
This note may include excerpts from previously published research. For access to the full reports, including analyst certification and important disclosures, investment thesis, valuation methodology, and risks to rating and price targets, please visit
Company-Specific Disclosures
Important disclosures, including price charts, are available and all Elite Wealth Limited covered companies by visiting, or emailing with your request. Elite Wealth Limited may screen companies based on Strategy, Technical, and Quantitative Research. For important disclosures for these companies, please e-mail
Options related research:
If the information contained herein regards options related research, such information is available only to persons who have received the proper option risk disclosure documents. For a copy of the risk disclosure documents, please contact your Broker’s Representative or visit the OCC’s website at
Other Disclosures
All research reports made available to clients are simultaneously available on our client websites. Not all research content is redistributed, e-mailed or made available to third-party aggregators. For all research reports available on a particular stock, please contact your respective broker’s sales person.
Ownership and material conflicts of interest Disclosure
Elite Wealth Limited policy prohibits its analysts, professionals reporting to analysts from owning securities of any company in the analyst’s area of coverage. Analyst compensation: Analysts are salary based permanent employees of Elite Wealth Limited. Analyst as officer or director: Elite Wealth Limited policy prohibits its analysts, persons reporting to analysts from serving as an officer, director, board member or employee of any company in the analyst’s area of coverage.
Country Specific Disclosures
India – For private circulation only, not for sale.
Legal Entities Disclosures
Mr. Ravinder Parkash Seth is the Managing Director of Elite Wealth Ltd (EWL, henceforth), having its registered office at Casa Picasso, Golf Course Extension, Near Rajesh Pilot Chowk, Radha Swami, Sector-61, Gurgaon-122001 Haryana, is a SEBI registered Research Analyst and is regulated by Securities and Exchange Board of India. Telephone:011-43035555, Facsimile: 011-22795783 and Website:
EWL discloses all material information about itself including its business activity, disciplinary history, the terms and conditions on which it offers research report, details of associates and such other information as is necessary to take an investment decision, including the following:
1. Reports
a) EWL or his associate or his relative has no financial interest in the subject company and the nature of such financial interest;
(b) EWL or its associates or relatives, have no actual/beneficial ownership of one per cent. or more in the securities of the subject company, at the end of the month immediately preceding the date of publication of the research report or date of the public appearance;
(c) EWL or its associate or his relative, has no other material conflict of interest at the time of publication of the research report or at the time of public appearance;
2. Compensation
(a) EWL or its associates have not received any compensation from the subject company in the past twelve months;
(b) EWL or its associates have not managed or co-managed public offering of securities for the subject company in the past twelve months;
(c) EWL or its associates have not received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months;
(d) EWL or its associates have not received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months;
(e) EWL or its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research report.
3 In respect of Public Appearances
(a) EWL or its associates have not received any compensation from the subject company in the past twelve months;
(b) The subject company is not now or never a client during twelve months preceding the date of distribution of the research report and the types of services provided by EWL